INDUSTRIAL IMPACT

AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients

AbCellera and Atlas Venture | August 04, 2022 | Read time : 01:00 min

AbCellera and Atlas
AbCellera and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ proven track record in forming innovative biotechnology companies and AbCellera’s unique ability to quickly deliver lead drug candidates to bring transformational new medicines to patients faster.

"AbCellera’s clinically validated platform lets us start discovery in a virtualized model that aligns well with our capital efficient investment strategy. This partnership supports our approach to value creation by allowing us to focus on building companies that aim to deliver impactful medicines to patients.”

Steven Robinette, Ph.D., Venture Partner at Atlas Venture

“Atlas has proven expertise in finding and transforming innovative scientific research into exciting new biotechs,” said Carl Hansen, Ph.D., CEO and President of AbCellera. “By eliminating their need to build internal antibody discovery capabilities at inception, we provide newly launched biotech ventures with a competitive advantage that empowers them to move faster and increase their probability of success. We look forward to working alongside Atlas’ entrepreneurs to unlock their breakthrough science and create new therapies for patients in need.”

Under the terms of the agreement, Atlas’ portfolio company will have the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and will be eligible to receive clinical and commercial milestone payments and royalties on net sales of products.

About Atlas Venture
Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups for over 25 years. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. 

About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. 

Spotlight

We’ve all been there as modern marketers catching up to the changing trends every now and then. Virtual event marketing is the new oil, the new currency that most of us are trying to win at. But more often than not we end up running into challenges like –

Spotlight

We’ve all been there as modern marketers catching up to the changing trends every now and then. Virtual event marketing is the new oil, the new currency that most of us are trying to win at. But more often than not we end up running into challenges like –

Related News

CELL AND GENE THERAPY

Spatial Biology CRO Flagship Biosciences Acquires Pharma Services Business from Interpace Biosciences

Flagship Biosciences, Inc. | September 01, 2022

Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma Solutions® a division of Interpace Biosciences and provider of cytogenetic, molecular pathology, and genomic profiling solutions. This acquisition follows a growth equity investment in Flagship from Ampersand Capital Partners, BroadOak Capital Partners, and Research Corporation Technologies. The strategic combination of Flagship and IPS creates a full repertoire of biomarker lab and analytic services to advance precision therapeutic development and adds a state-of-the-art laboratory in Research Triangle Park, NC. Flagship Biosciences offers cutting-edge spatial biology services, powered by its patented AI image analysis technology that improves the accuracy of tissue-based pathology by delivering thousands of measurements on every cell and enabling the discovery of biomarkers that might be missed using traditional histology methods. Experts in pathology and regulatory strategy, the team at Flagship offers advanced end-to-end biomarker and analytics services to support drug trials, biomarker discovery, and clinical diagnostics. They also offer guidance in the development of companion diagnostics. To better serve their biopharma and diagnostics clients, Flagship Biosciences will integrate the technologies and services of IPS to support all phases of clinical trials and diagnostic development in immuno-oncology, hematology, solid tumors, and various non-oncology sectors. Flagship Biosciences' expanded services menu will now include advanced molecular biomarker solutions, flow cytometry, cytogenetics, genomics, and bioinformatics solutions. New genomic profiling capabilities will enhance biomarker characterization and improve patient stratification for clinical trials and treatment selection. "By combining these organizations, we create a single-source provider offering a larger range of biomarker and analytics services while maintaining and expanding the proven expertise of each laboratory. This will allow our customers to gain deeper insights into their clinical projects through multiple biomarker testing paradigms with cohesive data and analytical capabilities, managed in a simplified project workflow." Trevor Johnson, CEO at Flagship Biosciences About Flagship Biosciences Founded in 2009 and headquartered in Broomfield, Colorado, Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data available. We are revolutionizing tissue analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Our services and technology dramatically improve on the data and interpretation from traditional pathology methods, eliminating variability associated with typical tissue assessments, and bringing new insights to tissue analysis results. We provide expert scientific consultation for every client. Our team interprets results, contextualizes tissue biology, and identifies the best course for success. For more information, please visit flagshipbio.com and follow us on Twitter and LinkedIn. About Interpace Pharma Solutions Based in Research Triangle Park, NC, Interpace Pharma Solutions provides complex molecular analysis services supporting clinical trials and diagnostic development. These services include genomic profiling, biomarker solutions, project and data management, bioinformatics analysis, and biorepository services. About Ampersand Capital Partners Founded in 1988, Ampersand is a middle market private equity firm with more than $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. About BroadOak Capital Partners BroadOak Capital Partners, with headquarters in Washington, DC, and San Francisco, is a life-sciences focused boutique financial institution that provides direct investment and investment banking services to companies in research tools and consumables, diagnostics, biopharma services, and adjacent markets. BroadOak has led or participated in investments in more than fifty companies across multiple funds and investment vehicles. About Research Corporation Technologies Research Corporation Technologies is a Tucson, Arizona based technology investment and management company that provides funding and development for promising life science and biomedical companies. RCT has assets of more than $500 million to advance technology and product development through flexible, long-term investment options.

Read More

CELL AND GENE THERAPY

Tiziana Life Sciences Announces Grant received by the Brigham and Women’s Hospital to Explore the Use of Intranasal anti-CD3 mAb

Tiziana Life Sciences Ltd. | September 16, 2022

Tiziana Life Sciences Ltd. a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that a Lawrence & Isabel Barnett Drug Development Program Grant will be awarded to the Ann Romney Center for Neurologic Diseases at the Brigham and Women’s Hospital by the ALS Association for the study of an intranasal anti-CD3 monoclonal antibody in an animal model of Amyotrophic Lateral Sclerosis (ALS). Howard L. Weiner, M.D., Co-Director of the Ann Romney Center for Neurologic Diseases at BWH and Chairman of Tiziana's Scientific Advisory Board, stated, “This prestigious research grant will be used to further study the role of intranasal anti-CD3 mAb in dampening the microglial activation which amplifies ALS disease progression. This research follows our recently presented positive findings on intranasal anti-CD3 mAb in Alzheimer’s Disease preclinical models of neuroinflammation. Additionally, we are currently studying foralumab, the first entirely human anti-CD3 mAb, in patients with secondary progressive multiple sclerosis.” Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana, remarked, “Intranasal foralumab has demonstrated potential across multiple Central Nervous System (CNS) indications. We are encouraged by the preclinical research using an intranasal anti-CD3 mAb in the neuroinflammatory related diseases of ALS and Alzheimer’s, as well as the impressive clinical benefits we have already shown for foralumab in patients with multiple sclerosis. While our initial focus is on our ongoing MS program which will continue to generate clinical read-outs, we are excited by foralumab’s potential to help highly debilitated ALS patients with limited therapeutic options and high unmet need.” “We have now seen the potential of intranasal foralumab to dampen microglial activation in three major neuroinflammatory-related diseases, which creates significant optionality for exploring its benefits in some of the most important and burdensome medical conditions of our time.” Matthew W. Davis, M.D., RPh, Chief Medical Officer of Tiziana About the Barnett Drug Development Grant The ALS Association’s Barnett Drug Development grant program supports preclinical drug discovery and development of new or repurposed treatments for ALS. There is an urgent need for new and improved therapies for ALS, as there is still no cure. The Lawrence and Isabel Barnett Drug Development Program is open to industry and academic investigators proposing to develop novel or repositioning approaches for ALS. The Association seeks applications for the preclinical assessment of therapeutics for ALS that have a high probability of reaching the clinic within three years. About Foralumab Foralumab the only entirely human anti-CD3 mAb, has shown reduced release of cytokines after IV administration in healthy volunteers and in patients with Crohn's disease. In a humanized mouse model it was shown that while targeting the T-cell receptor, orally administered foralumab modulates immune responses of the T-cells and enhances regulatory T-cells thereby providing therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy. Once a day treatment for 10 consecutive days with intranasal foralumab was both well tolerated and produced clinical responses in COVID-19 patients. Based on these studies, the intranasal and oral administration of Foralumab offers the potential to become a well-tolerated immunotherapy for autoimmune and inflammatory diseases by the induction of Tregs. About Tiziana Life Sciences Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

Read More

INDUSTRIAL IMPACT

Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal

Synaffix | September 07, 2022

Synaffix B.V. and Emergence Therapeutics AG announce that the Companies have entered into a licensing agreement of up to $360 million, providing Emergence access on a target-specific basis to Synaffix's proprietary antibody drug conjugate technologies comprising GlycoConnect™, HydraSpace™ and SYNtecan E™ linker-payload. Under the terms of the agreement, Synaffix will be eligible to receive up to $360 million in upfront and milestone payments plus royalties on commercial sales. The first program will commence at signature, with the option to expand the collaboration to additional targets. The agreement is the result of positive proof of concept data following a successful initial discovery research collaboration between the companies. Emergence will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies. Jack Elands, Chief Executive Officer of Emergence Therapeutics, commented: "This transaction demonstrates our commitment to the development of our pipeline of first-in-class and/or best-in-class ADCs. Beyond our lead program ETx-22, a next generation Nectin-4 ADC, we are actively advancing further programs to develop treatments for high unmet-need cancers. We are impressed with the Synaffix technology and are pleased to select it as a key component to accelerate our pipeline of ADCs." "This marks an important milestone for Synaffix as this is the 10th ADC developer who has licensed our innovative ADC technology to develop proprietary ADCs for their own pipeline. By consolidating all essential technologies within Synaffix, we have repeatedly enabled the development of best-in-class and first-in-class ADCs under a single technology license agreement. We are thrilled that Emergence has selected Synaffix as its long-term ADC technology partner and look forward to working closely with Emergence as they build out their portfolio of ADC candidates." Peter van de Sande, Chief Executive Officer of Synaffix About Synaffix B.V. Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform. In addition to GlycoConnect™ and HydraSpace™ technology, the toxSYN™ linker-payload platform rounds out a fully complementary technology platform that enables any company with an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix. The Synaffix platform enables a rapid timeline to clinic due to the established supply chain of technology components. Granted patents covering Synaffix' technology provide end-to-end protection of the manufacturing technology as well as the resulting products through at least 2035. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab and Macrogenics. About Emergence Therapeutics AG Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugates (ADC) to treat high-need cancers. Its lead program combines a highly specific antibody with optimized linker and payload technology to target Nectin-4 – an important target for a broad range of cancers which has been clinically validated as an ADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Emergence Therapeutics is also actively developing a pipeline of further first- or best-in-class ADCs driven by therapeutic need. Emergence is supported by a network of world-leading experts in immuno-oncology and a leading international investor syndicate. Emergence Therapeutics AG is based in Duisburg, Germany with a subsidiary in Marseille, France. For more information, please visit: www.emergencetx.com About The Synaffix ADC Platform Technology Synaffix' proprietary ADC technology platform consists of GlycoConnect™, HydraSpace™ and toxSYN™ technologies. Both GlycoConnect™ and HydraSpace™ are clinical-stage technologies that enable best-in-class ADCs with significantly enhanced efficacy and tolerability. GlycoConnect™ is a conjugation technology that exploits the native antibody glycan for site-specific and stable payload attachment and is tunable to DAR1, DAR2 or DAR4 formats. HydraSpace™ is a compact and highly polar spacer technology that is designed to further enhance therapeutic index, particularly with hydrophobic payloads. toxSYN™ is a linker-payload platform that spans key, validated MOAs for ADC product development, including SYNtecan E™ and SYNeamicin G™, among other linker-payloads.

Read More